Cutting the payment level for Medicare Part B drugs is a perennial budget proposal, but never gets very far in Congress. Now, thanks to the sequester, Part B payments have been cut from ASP+6% to ASP+4.3%. Will it stick?
Ever since Part B drug reimbursement switched to Average Sales Price plus 6% in 2004, there has been debate over whether that “plus 6” could be reduced to save some money for the Medicare program.
Budget cutters routinely throw out the idea of cutting the payment to ASP+4%, arguing that providers will still be making...
While Japanese government announces 8-15% price cuts for four drugs, including Leqembi, industry groups urge operational improvements to national cost effectiveness assessment scheme.
Vertex and Biogen are working with the Dutch government to ensure access for eligible patients.
The arrangement, which implies a behind the scenes negotiated discount, may signal a trend toward less price transparency in foreign markets as manufacturers parry Trump’s Most Favored Nation price demands.
